Patents by Inventor Leah C. Konkol

Leah C. Konkol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10640503
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Publication number: 20190062301
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 28, 2019
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
  • Publication number: 20190040058
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: July 18, 2018
    Publication date: February 7, 2019
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Patent number: 10047086
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 14, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Publication number: 20180179202
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Neil Lajkiewicz, Chunhong He, Kaijiong Xiao, Wenyu Zhu, Zhenwu Li, Song Mei, Chao Qi, Leah C. Konkol, Wenqing Yao
  • Publication number: 20180177784
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
  • Publication number: 20170369487
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 28, 2017
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Patent number: 9695168
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Patent number: 9676782
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 13, 2017
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Julie L. Engers, Leah C. Konkol
  • Publication number: 20170121302
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 7, 2016
    Publication date: May 4, 2017
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang
  • Patent number: 9493450
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: November 15, 2016
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Wenqing Yao
  • Publication number: 20160009712
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: July 9, 2015
    Publication date: January 14, 2016
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Publication number: 20150361081
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.
    Type: Application
    Filed: June 12, 2015
    Publication date: December 17, 2015
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Julie L. Engers, Leah C. Konkol
  • Publication number: 20150225394
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: February 12, 2015
    Publication date: August 13, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Leah C. Konkol, Ding-Quan Qian, Bo Shen, Wenqing Yao, Fenglei Zhang